Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 11/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906315 | 0.91 | NPC1 (0.56) | LRRK2GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7900427 | 0.89 | KMT2A (0.54) | LRRK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7910114 | 0.86 | LRRK2 (0.53) | LRRK2NPC1RAB9ASMN1; SMN2GRM5 | |
| SCHEMBL7913041 | 0.83 | SMN1; SMN2 (0.58) | LRRK2GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7899805 | 0.82 | LRRK2 (0.54) | LRRK2GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15886258 | 0.81 | BACE1 (0.60) | BACE1BACE2KCNH2CYP1A2CYP3A4 | |
| SCHEMBL7913781 | 0.81 | ALDH1A1 (0.52) | LRRK2GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7907942 | 0.81 | HSD11B1 (0.45) | LRRK2BACE1BACE2KCNH2GRM5 | |
| SCHEMBL7909381 | 0.80 | LRRK2 (0.57) | LRRK2GRM4GRM5 | |
| SCHEMBL3101805 | 0.80 | SMN1; SMN2 (0.52) | LRRK2GRM4NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100050-A1 | PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | GRM2, GRM1, GRM3 | LRRK2 1918/4885GRM4 7/4885NPC1 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.